C$0.72 -0.0 -2.7%
Last Trade - 20/04/21
| Market Cap | £38.1m |
| Enterprise Value | £30.5m |
| Revenue | £n/a |
| Position in Universe | 1020th / 2712 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Apr | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi. It operates through two divisions: HAVN Labs and HAVN Retail. HAVN Labs division is focused on development and formulation of regulated and novel psychoactive compounds. HAVN Retail division is focused on formulating and selling natural health products (NHPs) using compounds. The product lines of HAVN Retail include HAVN Immunity, HAVN Cognitive, HAVN Stress and HAVN Energy. Its formulations are being designed to target receptors and enzymes to support immune regulation, support the regulation and release of neurotransmitters that support mental cognition, to reduce stress response and to support mental energy.
| Last Annual | April 30th, 2020 |
| Last Interim | January 31st, 2021 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Canadian Securities Exchange |
| Shares in Issue | 90,335,741 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 3800 Wesbrook Mall, VANCOUVER, V6S 2L9, Canada |
| Web | https://havnlife.com/ |
| Phone | +1 604 6877130 |
| Contact | () |
| Auditors | DeVisser Gray LLP |
As of 20/04/21, shares in HAVN Life Sciences Inc are trading at C$0.72, giving the company a market capitalisation of £38.1m. This share price information is delayed by 15 minutes.
Shares in HAVN Life Sciences Inc are currently trading at C$0.72 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the HAVN Life Sciences Inc price has moved by % over the past year.
There are no analysts currently covering HAVN Life Sciences Inc.
HAVN Life Sciences Inc is scheduled to issue upcoming financial results on the following dates:
HAVN Life Sciences Inc does not currently pay a dividend.
HAVN Life Sciences Inc does not currently pay a dividend.
HAVN Life Sciences Inc does not currently pay a dividend.
To buy shares in HAVN Life Sciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in HAVN Life Sciences Inc are currently trading at C$0.72, giving the company a market capitalisation of £38.1m.
Here are the trading details for HAVN Life Sciences Inc:
Based on an overall assessment of its quality, value and momentum, HAVN Life Sciences Inc is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for HAVN Life Sciences Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HAVN Life Sciences Inc. Over the past six months, the relative strength of its shares against the market has been -31.59%. At the current price of C$0.72, shares in HAVN Life Sciences Inc are trading at -14.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for HAVN Life Sciences Inc.
We were unable to find the directors for HAVN Life Sciences Inc.
Here are the top five shareholders of HAVN Life Sciences Inc based on the size of their shareholding:
